| Name | Title | Contact Details |
|---|
Medical Practice Management Services is a Coeur D Alene, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lark Health is the leading virtual chronic disease management and prevention platform. Lark helps people stay healthy and in control of their conditions, such as Diabetes, Prediabetes, Cardiovascular Disease, and Anxiety from the comfort of their homes.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Kellogg Community Federal Credit Union is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lancaster, PA. To find more information about Kellogg Community Federal Credit Union, please visit www.kelloggcfcu.org
Bio-Tissue®, a subsidiary of TissueTech™, is the leader in regenerative biologic therapies and ocular hygiene solutions for eye care professionals. Established in 1997, Bio-Tissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals heal ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis dry eye, pterygium and dry eye. Eye care professionals understand that good medicine is based on good science. Bio-Tissue® prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for a range of ocular surface and lid margin diseases. Bio-Tissue® adheres to the FDA tissue and medical device guidelines.